Splenomegaly and splenectomy in sarcoidosis

Area of Science:

• Internal Medicine
• Pathology

Background:

• Sarcoidosis is a multisystem inflammatory disease.
• Splenic involvement, including granulomas and splenomegaly, occurs in some sarcoidosis cases.
• Splenomegaly can cause significant discomfort and hematological abnormalities.

Purpose of the Study:

• To investigate the natural history of splenic sarcoidosis.
• To evaluate the efficacy of splenectomy and corticosteroids in managing splenic sarcoidosis.
• To assess the impact of splenic involvement on the overall sarcoidosis progression.

Main Methods:

• Retrospective study of 30 patients with histologically confirmed splenic sarcoidosis.
• Analysis of clinical data, including splenomegaly, splenectomy, corticosteroid treatment, and hematological parameters.
• Longitudinal follow-up to observe disease progression and treatment outcomes.

Main Results:

• 24 out of 30 patients presented with splenomegaly.
• 16 patients underwent splenectomy, primarily for symptomatic splenomegaly.
• Corticosteroids provided temporary spleen size reduction, with rebound splenomegaly upon dose adjustment.
• Splenectomy successfully controlled hematological abnormalities in affected patients.
• Splenic involvement did not alter the natural history of sarcoidosis.

Conclusions:

• Splenectomy is an effective treatment for symptomatic splenomegaly and associated hematological abnormalities in sarcoidosis.
• Corticosteroid therapy offers only temporary relief for splenomegaly in sarcoidosis.
• Management of splenic sarcoidosis requires a tailored approach, considering both symptomatic relief and the overall disease course.